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Abstract: Among several promising new drug-delivery systems, liposomes represent an 
advanced technology to deliver active molecules to the site of action, and at present several 
formulations are in clinical use. Research on liposome technology has progressed from 
conventional vesicles (“first-generation liposomes”) to “second-generation liposomes”, in 
which long-circulating liposomes are obtained by modulating the lipid composition, size, and 
charge of the vesicle. Liposomes with modified surfaces have also been developed using several 
molecules, such as glycolipids or sialic acid. A significant step in the development of long-
circulating liposomes came with inclusion of the synthetic polymer poly-(ethylene glycol) (PEG) 
in liposome composition. The presence of PEG on the surface of the liposomal carrier has been 
shown to extend blood-circulation time while reducing mononuclear phagocyte system uptake 
(stealth liposomes). This technology has resulted in a large number of liposome formulations 
encapsulating active molecules, with high target efficiency and activity. Further, by synthetic 
modification of the terminal PEG molecule, stealth liposomes can be actively targeted with 
monoclonal antibodies or ligands. This review focuses on stealth technology and summarizes 
pre-clinical and clinical data relating to the principal liposome formulations; it also discusses 
emerging trends of this promising technology.
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Introduction
Clinical medicine possesses an extremely broad range of drug molecules currently 
in use, and new drugs are added to the list every year. One of the main goals of any 
treatment employing xenobiotics is to increase the therapeutic index of the drug while 
minimizing its side-effects. The clinical utility of most conventional chemotherapeutics 
is limited either by the inability to deliver therapeutic drug concentrations to the 
target tissues or by severe and harmful toxic effects on normal organs and tissues. 
Different approaches have been attempted to overcome these problems by providing 
“selective” delivery to the affected area; the ideal solution would be to target the 
drug only to those organs, tissues, or cells affected by the disease. Selected carriers, 
such as molecular conjugates and colloidal particulates, can be suitable for this 
purpose. Colloidal particulates result from physical incorporation of the drug into a 
particulate colloidal system such as liposomes, niosomes, micro- and nano-spheres, 
erythrocytes, and polymeric and reverse micelles. Among these carriers, liposomes 
have been most studied. Their attraction lies in their composition, which makes them 
biocompatible and biodegradable. They consist of an aqueous core entrapped by one 
or more bilayers composed of natural or synthetic lipids. Liposomes composed of 
natural phospholipids are biologically inert and weakly immunogenic, and they possess 
low intrinsic toxicity. Further, drugs with different lipophilicities can be encapsulated 
into liposomes: strongly lipophilic drugs are entrapped almost completely in the lipid 
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bilayer, strongly hydrophilic drugs are located exclusively in 
the aqueous compartment, and drugs with intermediate logP 
easily partition between the lipid and aqueous phases, both in 
the bilayer and in the aqueous core (Gulati et al 1998).
Liposomes can be classified according to their lamellarity 
(uni-, oligo-, and multi-lamellar vesicles), size (small, 
intermediate, or large) and preparation method (such as 
reverse phase evaporation vesicles, VETs). Unilamellar 
vesicles comprise one lipid bilayer and generally have 
diameters of 50–250 nm. They contain a large aqueous core 
and are preferentially used to encapsulate water-soluble drugs. 
Multilamellar vesicles comprise several concentric lipid 
bilayers in an onion-skin arrangement and have diameters 
of 1–5 µm. The high lipid content allows these multilamellar 
vesicles to passively entrap lipid-soluble drugs.
Since liposomes were first developed (around 1980) the 
related technology has made considerable progress, and 
several important formulations for the treatment of different 
diseases are now available commercially or in advanced 
clinical trials. As shown in Figure 1, the interest in liposome 
technology and clinical applications remains high, and almost 
800 papers and 50 reviews were published in 2005 alone.
The present review will briefly outline the characteristics 
of liposomes and look at the related problems and solutions 
proposed, with a focus on advanced liposome formulations. 
In particular, we revisit the literature relating to high-stability, 
long-circulating liposomes (stealth liposomes), their field 
of application, and future trends concerning novel stealth 
formulations.
Conventional liposomes
Liposomal formulations of several active molecules are 
currently in pre-clinical and clinical trials in different fields, 
with promising results. Two of the key problems in drug 
therapy (biodistribution throughout the body and targeting 
to specific receptors) can be overcome by using liposomal 
formulations: liposomes protect encapsulated molecules from 
degradation and can passively target tissues or organs that 
have a discontinuous endothelium, such as the liver, spleen, 
and bone marrow. On intravenous administration, liposomes 
are rapidly captured by the mononuclear phagocyte system 
(MPS) and removed from the blood circulation (Scherphof 
1985). This behavior has been exploited for efficient 
delivery of antiparasitic and antimicrobial drugs to treat 
infections localized in the mononuclear phagocytic system 
(eg, antimonial drugs against leishmaniasis) (Alving 1978; 
Agrawal and Gupta 2000; Basu and Lala 2004), or in order 
to encapsulate immunomodulators in activated macrophages 
in cancer models, to produce tumoricidal agents.
However, when the target site is beyond the MPS, efficient 
liposome uptake by the macrophages, and their consequent 
removal from circulation, is one of the main disadvantages 
for possible use of liposomes as drug delivery systems.
Binding of selected serum proteins (opsonins) is the first 
signal for removal of liposomes: the MPS does not recognize 
the liposomes themselves but, rather, recognizes opsonins, 
which are bound to the surface of the liposomes. A limited 
number of possible opsonizing proteins that affect the fate 
of liposomes have been identified, eg, immunoglobulins 
(Patel 1992), fibronectin (Falcone 1986; Patel 1992), beta 
2-glycoprotein (Chonn et al 1995), C-reactive protein (CRP) 
(Volanakis and Narkates 1981), and beta 2-macroglobulin 
(Murai et al 1995).
Complement components (Patel 1992; Devine et al 1994; 
Harashima et al 1994) comprise another important system 
able to recognize liposomes, which evolved as an immediate 
host defense against invading pathogens. This system acts 
through initiating membrane lysis and enhancing uptake 
by the MPS cells (neutrophils, monocytes, macrophages). 
In particular, the assembly of C5b-9 complexes (membrane 
attack complex: MAC) of the complement system is able to 
produces lytic pores, which induce cell lysis or, in the case 
of liposomes, the release of their contents. The complement-
dependent release of liposomal contents appears to be one 
of the dominant factors in determining the biological fate 
of liposomes. However, serum components that inhibit 
the phagocytosis of pathogens or particles, referred to 
as dysopsonins, have also been identified. Human serum 
albumin and IgA possess dysopsonic properties and their 
presence on particle surfaces has been shown to reduce 
recognition and phagocytosis. A balance between blood 
opsonic proteins and suppressive proteins has been found to 
regulate the rate of liposome clearance (Ishida et al 2002).
The instability of liposomes in plasma due to their 
Figure 1  Increase in scientific research on liposomes: papers (vertical line) 
and reviews (horizontal line) published (total numbers on vertical axis). Data 
obtained from Ovid-Medline search keyword “liposomes”.
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interaction with high (HDL) and low density (LDL) 
lipoproteins is another limitation, since this interaction 
results in the rapid release of the encapsulated drug into the 
plasma.
The physicochemical properties of liposomes, such 
as net surface charge, hydrophobicity, size, fluidity, and 
packing of the lipid bilayers, influence their stability and 
the type of proteins that bind to them (Chonn et al 1992; 
Oja et al 1996). One of the first attempts to overcome these 
problems was focused on manipulation of lipid membrane 
components in order to modify bilayer fluidity. Damen et 
al (2005) demonstrated that incorporation of cholesterol 
(CHOL), by causing increased packing of phospholipids in 
the lipid bilayer, reduces transfer of phospholipids to HDL; 
Senior (1982) demonstrated that liposomes obtained from 
phosphatidylcholine (PC) with saturated fatty acyl chains 
(with a high liquid crystalline transition temperature) or 
from sphingomyelin (SM) are more stable in the blood than 
liposomes prepared from PC with unsaturated fatty acyl 
chains.
Several approaches have also involved modulating 
liposome size and charge, so as to reduce MPS uptake. In 
general, larger liposomes are eliminated from the blood 
circulation more rapidly than smaller ones (Senior 1982). 
Small unilamellar vesicles (SUVs) have a half-life longer 
than that of multilamellar liposomes (MLVs) (500–5000 nm). 
This suggests that phagocytes can distinguish between the 
sizes of foreign particles.
Based on these observations, it is evident that the 
binding of opsonins to liposomes depends on the size of 
the liposomes, and that in consequence the enhanced MPS 
uptake of liposomes by the liver is likewise size-dependent 
(Harashima et al 1994).
Negatively charged liposomes have a shorter half-life in 
the blood than do neutral liposomes, although the contrary has 
also been found (Nishikawa 1990; Funato 1992); positively 
charged liposomes are toxic and thus quickly removed from 
circulation (Senior 1987).
The complement system has been reported to be activated 
by both negatively charged and positively charged liposomes 
in man (Chonn et al 1991; Marjan et al 1994; Bradley et al 
1998; Price et al 2001). Chonn et al (1991) report that, for 
both human and guinea-pig serum, surface charge is a key 
determinant in complement-system activation by liposomes: 
negatively charged liposomes activate the complement 
system via the classical pathway, while positively charged 
liposomes activate it via the alternative pathway. 
Clinical applications of conventional 
liposomes
Based on these studies, “conventional” liposomes composed 
of neutral and/or negatively charged lipids plus CHOL have 
been prepared; some of these formulations have reached 
the market (Table 1) or are now entering clinical trials. 
Ambisome
® (Gilead Sciences, Foster City, CA, USA) in 
which the encapsulated drug is the antifungal amphotericin 
B (Veerareddy and Vobalaboina 2004), Myocet
® (Elan 
Pharmaceuticals Inc., Princeton, NJ, USA) encapsulating 
the anticancer agent doxorubicin (Alberts et al 2004), 
and Daunoxome
® (Gilead Sciences), in which the drug 
incorporated is daunorubicin (Allen and Martin 2004), are 
the principal examples of such formulations. To obtain stable 
formulations incorporating a constant amount of drug, various 
mechanisms are exploited. Ambisome is lyophilized; Myocet 
is supplied in three separate vials, one containing doxorubicin 
as dry powder, one a solution of empty liposomes in citric 
buffer, and the third a solution of sodium carbonate. In this 
case drug entrapment must be achieved immediately prior to 
administration. Daunoxome is at present the only pure-lipid 
MPS-avoiding liposomal formulation; it is available as a 
stable ready-to-inject liposomal formulation.
By addition of sphingomyelin and saturated fatty acid 
chain lipids to the lipidic formulation, two commercial 
liposome formulations have been produced. A novel 
liposomal formulation of vincristine (Marqibo
®, formerly 
Onco TCS; Inex Pharmaceuticals Co., Vancouver, BC, 
Canada and Enzon Pharmaceuticals Inc., Bridgewater, NJ, 
USA), based on sphingomyelin–cholesterol uni-lamellar 
vesicles, has recently been shown to be efficacious in the 
treatment of relapsed non-Hodgkin’s lymphoma (Anonymous 
2004). Inex Pharmaceuticals Co. has in development two 
further candidate formulations: INX-0125
™ (liposomal 
vinorelbine) (Semple et al 2005) and INX-0076
™ (liposomal 
topotecan) (Tardi et al 2000), also based on the use of 
sphingomyelin–CHOL mixture.
Another liposomal formulation composed of hydrogenated 
soy phosphatidylcholine (HSPC) and CHOL and containing 
lurtotecan has been developed and named OSI-211
™ (OSI 
Pharmaceuticals, Inc., Melville, NY, USA). Clinical results 
have shown that incorporation of OSI-211 in the acid aqueous 
core of the vesicle, in addition to providing the known 
therapeutic advantages of a liposomal carrier, can also favor 
maintenance of lactone ring closure of lurtotecan (the active 
form), which increases stability of the active compound, 
consequently improving its tumor toxicity (Seiden et al 2004; 
Dark et al 2005).International Journal of Nanomedicine 2006:1(3) 300
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Two other liposome formulations employing saturated 
phospholipids have been launched for clinical
 development: 
Nyotran
® (Aronex Pharmaceuticals, The Woodlands, TX, 
USA) and Aroplatin
® (Antigenics Inc., Lexington, MA, 
USA). These are multilamellar liposomal formulations 
consisting
 of dimyristoyl phosphatidylcholine (DMPC) and 
dimyristoyl phosphatidylglycerol
 (DMPG). Nyotran contains 
nystatin A1, a membrane-active polyene antifungal antibiotic 
that is structurally related to amphotericin B (Anonymous 
1999; Arikan and Rex 2001). Aroplatin is a multilamellar 
liposomal formulation of cis-bis-neodecanoato-trans-R,R-
1,2-diaminocyclohexane platinum (II), a hydrophobic 
structural analog of oxaliplatin. Aroplatin is in clinical 
trials for a wide range of tumors and more recently for 
Table 1  Approved and emerging liposome formulations
Active agent  Composition  Stealth  Company, year of  Application  Trial phase 
(product name)      product marketing
DaunoXome
®   DSPC/CHOL  no  Nexstar Pharmaceuticals,   Kaposi’s sarcoma  Approved 
(daunorubicin)      1995
DOXIL
®/Caelyx
®  SoyHPC/CHOL/DSPE-PEG  yes  Sequus Pharmaceuticals,   Kaposi’s sarcoma  Approved 
(doxorubicin)      1997
Myocet
®/Evacet
®  EPC/CHOL  no  Elan Pharma, 2000  Metastatic breast cancer  Approved 
(doxorubicin)
SPI-077   SoyHPC/CHOL/DSPE-PEG  yes  Sequus Pharmaceuticals  Head and neck cancer,   Phase I/II 
(cisplatin)        Lung cancer
Lipoplatin™  SoyPC/DPPG/CHOL  yes  Regulon Inc.  Several cancer type  Phase II/III 
(cisplatin)
S-CKD602  —  yes  Alza Co.  Several cancer type  Phase I 
(camptothecin analog)
Aroplatin  DMPC/DMPG  no  Antigenics Inc  Colorectal cancer  Phase II 
(oxaliplatin analog)
Depocyt  DOPC/DPPG/CHOL/triolein  no  SkyePharma 1999  Lymphomatous meningitis  Approved
LEP-ETU  DOPE/CHOL/cardiolipin  no  NeoPharm Inc  ovarian, breast, and lung cancer  Phase I 
(paclitaxel)
LEM-ETU  DOPE/CHOL/cardiolipin  no  NeoPharm Inc  leukemia, breast, stomach, liver,   Phase I 
(mitoxantrone)        ovarian cancers
LE-SN38  DOPE/CHOL/cardiolipin  no  NeoPharm Inc  advanced cancer  Phase I 
(irinotecan)
MBT-0206  DOPE/DO-  no  MediGene AG  Anti-angiogenic proprieties  Phase I 
(paclitaxel)  trimethylammoniumpropane      Breast cancer
OSI-211  SoyHPC/CHOL  no  Enzon Co.  Ovarian cancer  Phase II 
(lurtotecan)        Head and neck cancer
Marqibo
®  DSPPC/CHOL/sphingosine  no  Inex Pharm  Non-Hodgkin’s lymphoma  Phase II/III 
(vincristine)
Atragen
®  DMPC, and soybean oil  no  Aronex Pharm  advanced renal cell ca,   Phase I/II  
(t-retinoic acid)        acute pro-myelocytic leucemia
INX-0125  DSPPC/CHOL/sphingosine  no  Inex Pharm  breast, colon and lung cancer  Preclinical 
(vinorelbine)          Phase I
INX-0076  DSPPC/CHOL/sphingosine  no  Inex Pharm  advanced cancer  Preclinical 
(topotecan)
Liposomal-Annamycin
®   DSPC/DSPG/Tween  no  MD Anderson CC  breast cancer  Phase II
Ambisome
®  SoyHPC/DSPPC/CHOL  no  Fujisawa USA Inc. and   Fungal infections in   Approved 
(amphotericin)      Nexstar Pharm 1997  immuno-compromised patients
Nyotran
®  DMPC/DMPG/CHOL  no  Aronex Pharm  Fungal infections in   Phase II/III 
(nistatin)        immuno-compromised patientsInternational Journal of Nanomedicine 2006:1(3) 301
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advanced solid tumors and B-cell lymphoma (Han et al 1993; 
Verschraegen et al 2003; Lu et al 2005).
Aronex Pharmaceuticals has also developed a liposomal-
all/trans/retinoic acid formulation (Atragen
®) containing 
tretinoin, dimyristoyl phosphatidylcholine (DMPC), and 
soybean oil. The formulation has shown efficacy in the 
treatment of acute promyelocytic leukemia and other retinoid-
responsive cancers (Ozpolat et al 2003).
Several interesting liposome preparations have been 
developed by NeoPharm (NeoPharm Inc., Waukegan, 
IL, USA including LEM-ETU
™, LEP-ETU
™, and LE-
SN38
™). In LEM-ETU, mitoxantrone (Ugwu et al 2005) 
is encapsulated in multilamellar liposomes (composed of 
dioleoyphosphatidyl choline [DOPC] and CHOL) after 
charge interaction with cardiolipin. LEP-ETU (Zhang et 
al 2005), a liposome-entrapped “easy to use” paclitaxel 
formulation, recently demonstrated bio-equivalence with 
Taxol
® (Bristol-Myers Squibb, New York, NY, USA)  and 
interesting activity in Phase I trials. This formulation, 
composed of DOPC, CHOL, and cardiolipin, is capable of 
carrying paclitaxel in the liposome bilayer at a maximum 
mole percent of about 3.5%. This is a higher loading capacity 
than those obtained in our previous studies with paclitaxel 
(Crosasso et al 2000) and docetaxel (Immordino et al 2003). 
In LE-SN38
™, the active metabolite of irinotecan (7-ethyl-
10-hydroxycamptothecin) is encapsulated in PC, CHOL, and 
cardiolipin liposomes (Zhang et al 2004a). LE-SN38 was in 
Phase I trials in 2004 (Kraut et al 2004).
Paclitaxel has also been encapsulated in other modern 
formulations of cationic lipid complexes (MBT-0206) that 
have been shown to be bounded and internalized selectively 
by angiogenic tumoral endothelial cells after intravenous 
injection. A Phase II clinical trial is in progress for candidate 
drug EndoTAG
™-1 (MediGene A.G., Martinsried, Germany) 
in the treatment of advanced pancreatic cancer (Eichhorn et 
al 2006).
Cytarabine is an anti-metabolite, anti-neoplastic 
agent used in clinical applications for acute lymphoid 
leukemia, myeloid leukemia and meningeal leukemia. 
DepoCyt
® (SkyePharma PLC, London, UK) is a slow-
release formulation of cytarabine designed for intrathecal 
administration in the treatment of neoplastic meningitis due 
to breast cancer (Jaeckle et al 2001; Bomgaars et al 2004). 
In DepoCyt, cytarabine is encapsulated in the aqueous 
compartment of a spherical 20-µm matrix comprised of lipids 
biochemically similar to normal human cell membranes 
(phospholipids, triglycerides and CHOL) (also called Depo-
Foam
™) (Mantripragada 2002).
Annamycin (3'-deamino-4'-epi-3'-hydroxy-2'-iodo-4-
demethoxy doxorubicin) is a “second-generation” highly 
lipophilic anthracycline developed by the M.D. Anderson 
Cancer Center. Its molecular design will be able to avoid 
the multi-drug-resistance mechanism of tumor cells, and its 
lipophilicity produces increased encapsulation in liposomes 
(Priebe and Perez-Soler 1993). Liposomal annamycin 
(composed of DMPC, DMPG, and Tween) (Andreff and 
Estey 2004) was in Phase II trials in late 2005 in patients with 
refractory or relapsed acute lymphocytic leukemia.
Long-circulating liposomes
The use of saturated phospholipids and cholesterol in the 
formulation of liposome delivery systems cannot fully 
overcome their binding with serum components, and 
the consequently decreased MPS uptake of the vesicles: 
saturation of the MPS with a previous administration of 
“empty” liposomes may be necessary. Moreover, SUVs 
possess the disadvantage of low aqueous entrapment volume, 
and the use of charged liposomes can be toxic. Several 
different strategies have been developed to overcome these 
difficulties by coating the surface of the liposomes with inert 
molecules to form a spatial barrier.
The first strategy studied was the preparation of liposomes 
mimicking the erythrocyte membrane; in this case the 
liposome surface was modified with gangliosides and sialic 
acid derivatives, such as monosialoganglioside (GM1) 
(Gabizon and Papahadjopoulos 1988; Allen et al 1989). The 
subsequent step was to increase the hydrophilicity of the 
liposomal surface by using hydrophilic polymers.
The mechanism whereby steric stabilization of liposomes 
increases their longevity in circulation has been extensively 
discussed (Drummond et al 1999). The basic concept is 
that a hydrophilic polymer or a glycolipid, such as PEG or 
GM1, possessing a flexible chain that occupies the space 
immediately adjacent to the liposome surface (“periliposomal 
layer”), tends to exclude other macromolecules from this 
space. Consequently, access and binding of blood plasma 
opsonins to the liposome surface are hindered, and thus 
interactions of MPS macrophages with such liposomes are 
inhibited.
By reducing MPS uptake, long-circulating liposomes 
can passively accumulate inside other tissues or organs. 
This phenomenon, called passive targeting, is especially 
evident in solid tumors undergoing angiogenesis: the 
presence of a discontinuous endothelial lining in the tumor 
vasculature during angiogenesis facilitates extravasation of 
liposomal formulations into the interstitial space, where they International Journal of Nanomedicine 2006:1(3) 302
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accumulate due to the lack of efficient lymphatic drainage of 
the tumor, and function as a sustained drug-release system. 
This causes the preferential accumulation of liposomes in 
the tumor area (a process known as enhanced permeation 
and retention effect or EPR) (Maeda et al 2001). Liposome 
formulations do not extravasate from the bloodstream into 
normal tissues that have tight junctions between capillary 
endothelial cells. These mechanisms appear to be responsible 
for the improved therapeutic effects of liposomal anticancer 
drugs versus free drugs. However, the processes involved 
in delivery of these carriers and release of active agent, the 
variability of such processes, and the degree to which the 
active agent is released into the tumor’s extracellular fluid 
or into tumor cells, are still unknown.
GM1 and glucoronide liposomes
Several glycolipids have been tested in studies of MPS 
uptake of liposomes after iv injection: the glycolipid GM1 
(a brain-tissue-derived monosialoganglioside) significantly 
decreased MPS uptake when incorporated on the liposome 
surface, and the formulation remained in blood circulation 
for several hours. GM1 grafted liposomes with a diameter 
in the 90–200 nm range have longer blood retention, with 
consequent accumulation in tumor tissues, than those out 
of this size range (Liu et al 1992). Large liposomes with a 
diameter of >300 nm preferentially accumulate in the spleen, 
whereas those with a diameter of <40 nm probably penetrate 
the interstitial spaces of the liver.
Unfortunately, the effect of GM1 liposomes in prolonging 
half-life in bloodstream has been observed only in mouse 
models. Among different gangliosides, only GM3-grafted 
liposomes showed increased circulation time in rats, whereas 
sialic-acid-modified liposomes exhibit prolonged blood 
retention in both mice and rats.
The degree of macrophage uptake depends on the 
concentration of GM1 in PC liposomes: a concentration of 
10 mol% decreased MPS uptake by 90%. This MPS-avoiding 
effect was reversed by the removal of the sialic acid moiety, 
demonstrating the important role played by this molecule in 
MPS-trapping avoidance (Yamauchi et al 1994).
On the basis of the studies reported above, two possibilities 
have been proposed to explain the mechanism of MPS 
avoidance by ganglioside liposomes. (1) Specific moieties 
(ie, GM1, but not other gangliosides in mice) grafted to the 
liposome surface reduce opsonization. (2) These moieties 
bind dysopsonins, reducing recognition by the MPS. It has 
also been suggested that the topology of carboxyl groups 
on the liposome surface plays an important role in liposome 
circulation time. One problem for the extensive use of sialic 
acid is its cost, a fact which stimulated the investigation 
of other derivatives, including glucuronic acid (Park et al 
1992). Oku and Namba (2005) recently summarized their 
research on glucuronate-modified long circulating liposomes. 
Utilizing palmityl-D-glucuronide, they obtained reduced 
MPS recognition in vitro, reduced hepatic accumulation in 
vivo, and consequently increased tumor accumulation and 
thus therapeutic efficacy of adriamicin encapsulated in long 
circulating liposomes.
Other recent interesting applications of GM-coated 
liposomes involve their use for oral administration and 
delivery to the brain. In particular, Taira et al (2004) suggest 
that among liposomal formulations used as oral drug 
carriers, those containing GM1 and GM type III have better 
possibilities of surviving through the gastrointestinal tract. 
Mora et al (2002) observed higher brain-tracer uptake for 
GM1 liposomes than for control liposomes in the cortex, 
basal ganglia, and mesencephalon of both hemispheres; 
conversely, no significant changes were observed in liver 
uptake or blood concentration of the tracer.
PEG-coated liposomes (stealth 
liposomes)
Among the different polymers investigated in the attempt 
to improve the blood circulation time of liposomes, 
poly-(ethylene glycol) (PEG) has been widely used as 
polymeric steric stabilizer. It can be incorporated on the 
liposomal surface in different ways, but the most widely 
used method at present is to anchor the polymer in the 
liposomal membrane via a cross-linked lipid (ie, PEG- 
distearoylphosphatidylethanolamine [DSPE] as schematized 
in Figure 2) (Allen et al 1991, 2002).
Figure 2  Chemical structures of distearoylphophatidylcholine (DSPC), 
distearoylphophatidylethanolamine after conjugation with poly-(ethylene glycol) 
(PEG) (DSPE-PEG) and DSPE-PEG linked with a targeting moiety.
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PEG (CAS number 25322-68-3) is a linear polyether 
diol with many useful properties, such as biocompatibility 
(Powell 1980), solubility in aqueous and organic media 
(Powell 1980), lack of toxicity, very low immunogenicity 
and antigenicity (Dreborg and Akerblom 1990), and good 
excretion kinetics (Yamaoka et al 1994). These properties 
allow its use in a variety of applications (Harris 1992), 
including the biomedical field.
Moreover, unlike GM1, molecular weight and structure of 
PEG molecules can be freely modulated for specific purposes, 
and it is easier and cheaper to conjugate the polymer with 
the lipid.
Poly-ethylene glycols have been used to derivatize 
therapeutic proteins and peptides, increasing drug stability 
and solubility, lowering toxicity, increasing half-life 
(Caliceti and Veronese 2003), decreasing clearance and 
immunogenicity. These benefits have been particularly 
observed using branched PEG in the derivatization 
(Monfardini and Veronese 1998). For the most part, reaction 
with PEG derivatives does not alter the mechanism of action 
of a therapeutic protein; rather it enhances its therapeutic 
effect by altering its pharmacokinetics. PEG-ademase 
(utilized to treat immunodeficiency), PEG-visomant (human 
growth hormone), PEG-aspargase (for leukemias), PEG-
interferon-alpha (for chronic hepatitis C), PEG-aldesleukin 
(PEG-IL-2) (an anticancer agent), and PEG-filgrastim (for 
chemotherapy-induced transferase neutropenia) are the 
principal PEGylated proteins in clinical use (Mahmood and 
Green 2005).
Surface modification of liposomes with PEG can be 
achieved in several ways: by physically adsorbing the 
polymer onto the surface of the vesicles, by incorporating 
the PEG-lipid conjugate during liposome preparation, or 
by covalently attaching reactive groups onto the surface of 
preformed liposomes.
Grafting PEG onto liposomes has demonstrated several 
biological and technological advantages. The most significant 
properties of PEGylated vesicles are their strongly reduced 
MPS uptake and their prolonged blood circulation and thus 
improved distribution in perfused tissues. Moreover, the PEG 
chains on the liposome surface avoid the vesicle aggregation, 
improving stability of formulations.
Needham et al (1992) demonstrated that the presence of 
PEG on the liposome surface provides a strong interbilayer 
repulsion that can overcome the attractive Van der Waals 
forces, thus stabilizing liposome preparations by avoiding 
aggregation. In particular, from X-ray analysis of bilayers 
incorporating PEG1900-lipid, their research showed that the 
grafted polymer moiety extends about 50Å from the lipid 
surface and gives rise to strong inter-membrane repulsive 
forces.
Regarding MPS uptake, Blume et al have found that 
the increased blood circulation time is due to a reduced 
interaction with plasma proteins and cell-surface proteins 
(Blume 1993; Vert and Domurado 2000), although other 
studies have found no direct evidence of this reduced 
interaction with plasma components (Johnstone et al 2001). 
One possible explanation for the reduced interaction is the 
steric hindrance effect, which is generated by the surface-
grafted methoxy-PEG molecules. Complement fixation on 
PEG-bearing liposomes thus appears to occur in a cryptic 
location inaccessible to ligation to complement receptors. 
Another possible contributor to the stealth behavior of such 
vesicles is competition for CR3 between surface-bound and 
free-complement proteins iC3b. Furthermore, degradation 
of surface-bound C3b to fragments inhibiting recognition 
by phagocytic complement receptors might also explain 
the anti-phagocytic effect. Studies with freshly isolated 
macrophages have also indicated the presence of unidentified 
serum factors (called dysopsonins) that act synergistically 
with the steric barrier of long circulating particles, thereby 
further suppressing particle recognition by phagocytic cells 
(Moghimi et al 1993; Johnstone et al 2001).
A number of reports have indicated that PEG does not 
completely avoid cumulative uptake by cells of the MPS, 
and an interesting review updates progress in this area. 
Moghimi and Szebeni (2003) critically examine the supposed 
mechanisms that contribute to prolonged circulation times of 
sterically protected liposomes. They point out that PEGylated 
liposomes are not completely biologically inert and that there 
is some evidence the polymer can still induce activation of 
complement systems: a PEGylated liposomal doxorubicin 
(PLD) (DOXIL
® in the US, Caelyx
® in Europe, Schering-
Plough, Kenilworth, NJ, USA) (Gabizon and Muggia 1998), 
is a strong activator of the human complement system, with 
activation taking place within minutes.
The behavior of PEGylated liposomes depends on the 
characteristics and properties of the specific PEG linked 
to the surface. Figure 3 represents the regimens proposed 
by deGennes, when polymers are attached to the liposome 
surface, depending on the graft density of the polymer (de 
Gennes 1980). The molecular mass of the polymer, as well 
as the graft density, determine the degree of surface coverage 
and the distance between graft sites.
The most evident characteristic of PEG-grafted liposomes 
(PEGylated-liposomes) is their circulation longevity, International Journal of Nanomedicine 2006:1(3) 304
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rigid polymer, like dextran, grafted to liposomes and used in 
comparable quantities, does not cause an analogous decrease 
in liposome-protein interactions.
In liposomes composed of phospholipids and cholesterol, 
the ability of PEG to increase the circulation lifetime of 
the vehicles has been found to depend on both the amount 
of grafted PEG and the length or molecular weight of the 
polymer (Allen et al 1991). In most cases, the longer-chain 
PEGs have produced the greatest improvements in blood 
residence time. For example, Allen et al (1991) reported 
that blood levels were higher for SM/PC/CHOL/DSPE-PEG 
liposomes with longer molecular weight PEG (ie, PEG 1900 
and PEG 5000) than for liposomes containing PEG-lipid 
with a shorter chain PEG (ie, PEG 750 and PEG 120). The 
presence of PEG 2000 doubled the amount of lipid remaining 
in the plasma compared to formulations containing PEG 
350 to 750.
The area of protection of PEG molecules of different 
molecular weights may be calculated: the calculation is based 
on a simple approach that was developed by Torchilin and 
Papisov (Torchilin and Papisov 1994).
A conclusive link has not yet been established between 
chemical and physical properties of PEG and its ability to 
extend circulation lifetime. Although the accepted opinion is 
that PEG increases circulation longevity of drug carriers by 
reducing or preventing protein binding and/or by inhibiting 
cell binding/uptake, there is sufficient conflicting data to 
warrant a reassessment of the mechanism(s) by which 
surface grafted PEGs improve liposome properties (Allen 
et al 2002).
Subcutaneous administration of PEGylated liposomes 
also appears interesting; this administration route could 
become very important, especially for targeting to the lymph 
nodes and to achieve sustained drug release in vivo. Targeting 
liposomes to the lymph nodes for administration of antitumor, 
antibacterial, and antiviral drugs is of particular interest, 
and the pharmacokinetics and biodistribution of PEG-
DSPE liposomes have been examined after subcutaneous 
administration (Allen et al 1993). Furthermore, the use 
of subcutaneously administered liposomes in the field of 
vaccination and rheumatism, with the aim of prolonging 
release of antigens or forming a local drug depot, is also in 
the focus of interest (Babai et al 1999; Corvo et al 1999). 
PEG-coating on liposomal surface may have a negative effect 
on lymph node uptake (reduced adsorption by phagocytosis). 
However, as hypothesized above, lymphatic absorption 
from the s.c. injection site may increase as a results of the 
steric stabilization effect and, therefore, the net amount of 
Figure 3  Schematic diagrams of poly-(ethylene glycol) (PEG) configurations 
regimes (mushroom, brush and pancake) for polymer grafted to the surface of 
liposome bilayer.
Figure 4  Plasma values obtained from mice iv injected determined by 
14C 
radioactivity associated to docetaxel in Tween 80 (crosses), docetaxel in 
conventional (black squares), and in PEGylated (gray squares) liposomes.
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regardless of surface charge or the inclusion of stabilizing 
agent such as cholesterol. Figure 4 represents the degree of 
longevity as determined by a pharmacokinetic evaluation 
of PEGylated liposomes containing docetaxel (Immordino 
et al 2003).
The ability of the hydrophilic shell of PEG to avoid 
aggregation between liposomal particles and to decrease the 
extent of particle–protein interaction in biological fluids is 
due not only to the molecular mass of the bound polymer and 
its uniformity (“molecular cloud”) but also to its considerable 
conformational flexibility (Torchilin et al 1994a). A more 
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liposomes taken up by the lymph nodes may be slightly 
higher despite the stealth effect. Indeed Oussoren and 
Storm (1997) compared liposome formulations composed 
of ePC/CHOL and DPPC/CHOL with or without PEG 2000 
or 5000 (5 mol%) with diameter 70 or 150 nm. After s.c. 
administration, the highest blood peak was in all cases that 
of the PEGylated liposomes; the authors concluded that “the 
results did not indicate that steric stabilization of liposome 
has profound effects on lymphatic uptake”.
Although these favorable characteristics have extended 
clinical applications of PEGylated liposomes, the evidence 
suggests some caution is needed, and that investigation 
of some aspects in greater depth, such as multiple dose 
administration or biodistribution in tumor tissues, is 
indicated.
Ishida et al (2005) and Laverman et al (2001) recently 
reported that intravenous injection in rats of PEG-grafted 
liposomes may significantly alter the pharmacokinetic 
behavior of a second dose when this second dose is 
administered after an interval of several days. This 
phenomenon, called “accelerated blood clearance” (ABC), 
appears to be inversely related to the PEG content of 
liposomes. By the same token, an inverse relationship has 
been observed between dose and magnitude of the ABC 
effect.
Stealth liposomes are important in cancer treatment for 
their passive targeting effect, which may lead to preferential 
accumulation in tumor tissue, but this phenomenon is not 
fully understood: Stealth liposomes are able to lodge in the 
interstitial spaces among tumor cells but, once in the tumor 
area, they locate in the extracellular fluid surrounding the 
tumor cell without entering it. Thus, to deliver the active 
form of an anticancer agent, such as doxorubicin or cisplatin, 
the drug must be released from the liposomes into the tumor 
extracellular fluid and then diffuse into the cell (Harrington 
et al 2000a, 2000b). As a result, the ability of liposomes to 
carry the anticancer agent to the tumor (which depends on 
their stability) and to release it into the tumor extracellular 
fluid (depending on membrane composition and fluidity) are 
equally important factors in determining the anti-tumor effect 
of liposome-encapsulated anticancer agents. Unfortunately, 
little is known of the kinetics of drug release from liposomes 
into the interstitial space: only the free drug can penetrate 
into the solid tumor, and it is difficult to determinate the 
ratio between free/liposome-encapsulated drug in the tumor 
extracellular fluid (Zamboni et al 2004).
Current research on PEG liposomes has concentrated on 
attaching PEG to the liposome surface in a removable fashion, 
in order to facilitate subsequent liposome capture by the cells. 
After PEG liposomes accumulate at the target site through the 
EPR effect, the PEG coating is detached under the action of 
local pathological conditions (decreased pH in tumors). New, 
detachable PEG conjugates have been described (Zalipsky et 
al. 1999) in which the PEG release process is based on mild 
thiolysis of the dithiobenzylurethane linkage between PEG 
and an amino-containing substrate (such as PE).
Clinical applications of stealth 
liposomes
PEGylated liposomal doxorubicin (PLD) (DOXIL/ Caelyx) 
was the first and is still the only stealth liposome formulation 
to be approved in both the USA and Europe for treatment of 
Kaposi’s sarcoma (Krown et al 2004) and recurrent ovarian 
cancer (Rose 2005). DOXIL/Caelyx is now undergoing trials 
for treatment of other malignancies such as multiple myeloma 
(Hussein and Anderson 2004), breast cancer (Robert et al 
2004), and recurrent high-grade glioma (Hau et al. 2004). 
Several studies are under way to investigate the anticancer 
activities of PLD in combination with other therapeutics, 
including the taxanes (paclitaxel or docetaxel) (Briasoulis 
et al 2004; Vorobiof et al 2004), temozolomide (Temodal
® 
Schering-Plough, Kenilworth, NJ, USA) (Awada et al 2004), 
and vinorelbine (Katsaros et al 2005).
The rigid bilayer of PLD is composed of HSPC, CHOL, 
and mPEG-DSPE (molecular weight 2000) at a molar ratio 
of 55:40:5. Liposomes with a mean diameter of 85 nm are 
able to incorporate doxorubicin at a concentration of 2 mg/
mL. The pharmacokinetics is very slow: plasma elimination 
follows a biexponential curve, with half-lives of 1.5 and 45 
hours (median values); in comparison, plasma half-lives are 
0.2 hours for free drug, 2–3 hours for Myocet and 5 hours 
for Daunoxome. Nearly 100% of the drug detected in the 
plasma after PLD injection was in liposome-encapsulated 
form; plasma clearance is clearly slow (0.1 L/hour) and the 
distribution volume small (4 L).
Due to its pharmacokinetic behavior, cardiotoxicity, 
myelosuppression, alopecia and nausea are significantly 
decreased with PLD compared with an equi-effective 
dose of conventional doxorubicin. These bio-distribution 
characteristics also make skin treatment of localized cancers 
such as Kaposi’s sarcoma possible; on the other hand, due to 
its reduced clearance, the palmar-plantar skin reaction and 
stomatitis/mucositis are the chief dose-related toxicities of 
PLD (Lyass et al 2000).
Another stealth liposome formulation is SPI-077
™ (Alza 
Corporation, Mountain View, CA, USA), in which cisplatin International Journal of Nanomedicine 2006:1(3) 306
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is encapsulated in the aqueous core of sterically stabilized 
liposomes (fully hydrogenated soy HSPC, CHOL, and 
DSPE-PEG). The stealth behavior of these compounds is 
evident from their apparent half-life of approximately 60–100 
hours. Phase I/II clinical trials have been run to treat head 
and neck cancer and lung cancer (Kim et al 2001). Although 
the toxicity profile was promising, the therapeutic efficacy 
requires improvement (Harrington et al 2001). To obtain the 
desired balance between encapsulation and release of cisplatin 
from liposomes, another formulation was evaluated by Alza 
Corporation (SPI-077 B103); they chose B103, in which 
HSPC is replaced by unsaturated phospholipids, because of 
its greater theoretical propensity to release cisplatin (Alza 
Corporation, data on file). However, Zamboni et al (2004) 
were not able to detect released cisplatin in in vitro systems, 
plasma, or tumor extracellular fluid after administration of 
either stealth formulation of liposomal cisplatin. 
Recently, S-CKD602 (Alza Corporation), a PEGylated 
stealth liposomal formulation
 of CKD-602, which is a semi-
synthetic analog of camptothecin, was submitted for a Phase 
I trial. After administration of S-CKD602 at doses of 0.5 mg/
m
2, the plasma
 AUC was 50-fold that of non-liposomal CKD-
602; S-CKD602 showed minimal toxicity and interesting 
activity (Zamboni et al 2005).
Lipoplatin
™ (Regulon Inc. Mountain View, CA, USA) 
is another liposomal cisplatin formulation composed of 
dipalmitoyl phosphatidyl glycerol (DPPG), soy PC, CHOL, 
and mPEG2000-DSPE. Its reported half-life is 60–117 hours, 
depending on the dose (Boulikas et al 2005; Stathopoulos et al 
2005). The study found that Lipoplatin has no nephrotoxicity 
up to a dose of 125 mg/m
2 every 14 days without the serious 
side effects of cisplatin.
Mitoxantrone (Novantrone
®, Wyeth Lederle, Madison, 
NJ, USA) is a drug used for the treatment of acute myeloid 
leukemia, multiple sclerosis, and prostate cancer. Despite 
the promising early results of a PEGylated mitoxantrone 
formulation (dlakha-Hutcheon et al 1999) the only currently 
existing formulations with lipids and cardiolipine are in 
clinical trials (as described above).
PEG alternatives
Despite the well-developed chemistry of PEG coupled 
to pharmaceuticals, the search for alternative polymers 
is ongoing; this might be explained both by the patent 
limitations on PEG and its derivatives, and by the hope of 
achieving even better control over the properties of modified 
drugs and drug carriers. Suggested theoretical models 
for modified protein behavior, and the experimental data 
available, enable some general requirements for polymers 
to confer steric protection to drug carriers to be formulated. 
These polymers should be soluble, hydrophilic, have highly 
flexible main chain, and high biocompatibility. Synthetic 
polymers, such as poly(vinyl pyrrolidone) (PVP) and 
poly(acryl amide) (PAA), are the most prominent examples 
of other potentially protective polymers (Torchilin et al 
1994b, 1994c, 1995). Liposomes containing DSPE covalently 
linked to poly(2-methyl-2-oxazoline) or to poly(2-ethyl-2-
oxazoline) also exhibit extended blood circulation time and 
decreased uptake by the liver and spleen (Woodle et al 1994). 
Similar observations have been reported for phosphatidyl 
polyglycerols (Maruyama et al 1994).
More recent papers describe long circulating liposomes 
prepared using poly[N-(2-hydroxypropyl) methacrylamide] 
(Whiteman et al 2001), amphiphilic poly-N-vinylpyrrolidones 
(Torchilin et al 2001), L-amino-acid-based biodegradable 
polymer–lipid conjugates (Metselaar et al 2003), and 
polyvinyl alcohol (Takeuchi et al 2001). All groups of 
polymer-coated liposomes reported have been found to 
extend blood circulation time, while liver capture was 
diminished. These results are comparable with those for PEG-
liposomes; the efficacy of the steric effect quite naturally 
depends on the quantity of incorporated polymer. The 
prolonged circulation time of polyvinyl alcohol-(molecular 
weight: 20000) coated liposomes (1.3 mol% coating) was 
comparable with that of a stealth liposome prepared with 8 
mol% of DSPE–PEG2000.
Also, L-amino-acid-based polymers also showed 
prolonged circulation time and reduced uptake by the MPS, 
to the same extent as DSPE–PEG2000. Furthermore, these 
polymers appear to be attractive alternatives for designing 
long-circulation liposomes, because they have the advantage 
of being biodegradable.
Targeted liposomes
To increase liposomal drug accumulation in the desired 
tissues, producing higher and more selective therapeutic 
activity, the use of targeted liposomes has been suggested. 
This involves the coupling of targeting moieties capable of 
recognizing target cells, binding to them, and inducing the 
internalization of liposomes or encapsulated drugs. Targeting 
moieties include monoclonal antibodies (MAb) or fragments, 
peptides, growth factors, glycoproteins, carbohydrates, or 
receptor ligands (Lopes De Menezes et al 1999; Sapra and 
Allen 2003; Medina et al 2004). Targeted liposomes offer 
various advantages over individual drugs targeted by means 
of polymers or antibodies. One of the most compelling International Journal of Nanomedicine 2006:1(3) 307
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advantages is the dramatic increase in drug amount that 
can be delivered to the target. Furthermore, the number of 
ligand molecules exposed on the liposome surface can be 
increased, improving ligand avidity and degree of uptake. 
Immunoliposomes also provide a “bystander killing” effect, 
because the drug molecules can diffuse into adjoining tumor 
cells.
In order to behave in this fashion, immunoliposomes are 
built so as to be long-circulating and non-immunogenic, using 
the stealth technique. Briefly, a PEG (MW 3400) derivative 
of PE or DSPE containing a maleimide group at the end 
of the PEG chain is mixed into the liposome formulation 
(Figure 2). After liposome preparation, reduced thiol groups 
of Fab or scFv fragments are joined via surface linkage to 
the maleimide group of the aforementioned PEG-liposome, 
obtaining a stable thioether bond. This method for preparing 
immunoliposomes starting from preformed liposomes is 
the most widely used. Alternatively, commercially available 
doxorubicin-loaded long-circulating liposomes (DOXIL) 
have been modified by post-insertion of a monoclonal 
antibody. MAb, modified with DSPE–PEG conjugate, 
in which the free PEG terminus is activated with the p-
nitrophenylcarbonyl group, has been inserted into preformed 
liposomes (Lukyanov et al 2004). Therapeutic targets and 
immunoliposomal compositions are reported in Table 2.
At present, the only immunoliposome formulation 
undergoing clinical trials is the PEGylated liposome DXR 
targeted with the F(ab')2 fragment of the human MAb 
GAH, which is able to recognize gastric, colon, and breast 
cancer cells (Matsumura et al 2004). Another important 
target antigen is the p185 HER2/neu glycoprotein (HER2), 
a member of the epidermal growth factor receptor family. 
This antigen is suitable for targeting because, although HER2 
is expressed in healthy tissue, overexpression is unique to 
tumors, specifically some human breast cancers (25%–30% 
of cases), gastric, colon, ovarian, and non-small-cell lung 
carcinoma (Baselga and Metselaar 2000).
The monoclonal antibody anti-HER2 trastuzumab 
(Herceptin
®, Genentech Inc., Vacaville, CA, USA)  was the 
first humanized Mab approved by the FDA and in the EU as 
monotherapy for metastatic breast cancer. This antibody is 
widely used in breast cancer, both alone and in combination 
with chemotherapy agents, and two recent papers describe 
the GMP- compliant process for producing the F5 single-
chain Fv antibody fragment-PEG-lipid conjugate; therapeutic 
assemblies are made by post-insertion into preformed 
doxorubicin-encapsulating liposomes (Nellis et al 2005a, 
2005b).
In the last few years, antibody-based therapeutics have 
emerged as important components of therapies for an 
increasing number of human malignancies (Adams and 
Weiner 2005) and it is expected that several immunolipo-
somes will be in trials in the near future.
The main therapeutic area for immunoliposome applica-
tion is against cancer, but interesting papers describe other 
applications, such as reducing hemorrhagic transformation 
after thrombolytic therapy with tissue plasminogen activator 
in cerebral ischemia (Asahi et al 2003).
Other ligands have been used to specifically target stealth 
liposomes to receptors over-expressed in cancer cells. Folic 
acid, which has been used for liposome-specific targeting of 
DXR, daunorubicin, cisplatin, and other drugs, is one of the 
most extensively studied (for a recent review (Stephenson et 
al 2004)) and it has been proposed for boron neutron capture 
therapy (Stephenson et al 2003). Transferrin is a popular 
ligand for specific delivery of anticancer drugs, proteins and 
Table 2  Targeted liposomes in advanced phase of trial
Targeted with  Encapsulated drug  Disease  References
Anti-HER2 (trastuzumab)  DOXIL
®  breast, ovarian cancer   (Park et al 2002)
Anti-EGF  doxorubicin, vinorelbine,   solid tumors  (Mamot et al 2003) 
  methotrexate, DNA
Anti CD19  vincristine  lymphoma  (Tseng et al 1999)
Anti CD22  doxorubicin  anti-B-cell lymphoma  (Lundberg et al 2000)
Anti CD19  imatinib  ALL  (Harata et al 2004)
Anti-beta1 integrin  doxorubicin  several cancers  (Sugano et al 2000)
Anti GD2  doxorubicin  neuroblastoma  (Pastorino et al 2003)
GAH MAb  doxorubicin   gastric, colon and breast cancer  (Hamaguchi et al 2004)
Anti-EGF receptor  RNA  brain cancer  (Zhang et al 2004b)International Journal of Nanomedicine 2006:1(3) 308
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genes to malignant cells (Ishida et al 2001) as well as for 
boron neutron capture therapy (Maruyama et al 2004).
Sigma receptors (subtype of opioid receptor) have 
recently been proposed as an interesting target for different 
malignancies (breast, melanoma, prostate). An anisamide-
derivatized stealth liposomal formulation (DXR) showed 
high specific toxicity and superior therapeutic effect versus 
untargeted liposomes (Banerjee et al 2004) and recently 
haloperidol-associated stealth liposomes can efficiently target 
genes to sigma receptor overexpressing breast cancer cells 
(Mukherjee et al 2005).
Further, peptides involved in cell-to-cell interactions 
have been used as targeting agents for liposomes (now 
in preclinical trials). Targeting with L-peptide increased 
liposomal DXR toxicity on nasopharyngeal cells (Lee et al 
2004), while vasoactive intestinal peptide 28-mer conjugated 
with (
99mTc) loaded liposome increased the imaging of breast 
cancer cells (Dagar et al 2003). In addition, stealth liposomes 
(DXR or 5-FU) have been targeted through RGD-sequence 
peptides to the integrin of tumor vasculature, demonstrating 
interesting activity on neuroblastoma, melanoma, and colon 
in vivo models. Stealth liposomes conjugated with sequences 
of an angiogenic homing peptide (for instance GPLPLR, 
APRPG) were able to suppress tumor neovasculature in 
colon, melanoma and sarcoma cells growing in mice (Kondo 
et al 2004; Asai and Oku 2005).
Liposome applications
Cationic liposomes for gene delivery
Among various synthetic carriers currently in use in gene 
therapy, cationic liposomes are the most suitable transfecting 
vectors. Gene encapsulation in liposomal vesicles allows 
condensation of DNA plasmid into a highly organized 
structure, and protects DNA against degradation during 
storage and in the systemic circulation of the gene encoding 
a therapeutic protein. Moreover, structural organization of 
the gene-delivery system must bypass the cell membrane and 
facilitate endosomal escape, avoiding DNA degradation in 
the lysosomal compartment (Figure 5).
Numerous cationic lipids have been tested in the 
formulation of liposomes for gene delivery (the structural 
formulas of some of them are presented in Figure 
6). Transfection efficiency is strongly affected by the 
presence of three components in the structure of these 
lipids: a positively charged head-group that interacts with 
negatively charged DNA, a linker group (which determines 
the lipid’s chemical stability and biodegradability), and 
a hydrophobic region to anchor the cationic lipid into 
the bilayer. Among these, the most often used are N-[1- 
dioleyloxy)propyl]-N,N,N-trimethylammonium (DOTMA) 
and dioleoylphophatidylethanolamine (DOPE) in a 1:1 
phospholipid mixture (Lipofectin
®, Invitrogen Corporation, 
Carlsbad, CA, USA). Other commercially-available 
lipids are 2,3-dioleyloxy-N-[2(sperminecarboxamido)et
hyl]-N,N-dimethyl-1-propanammonium trifluoroacetate 
(DOSPA or LipofectAMINE
®), 1,2-bis(oleoyloxy)-3-(trim
ethylammonio)propane (DOTAP), 1,2-dimystyloxypropyl-
3-dimethylhydroxyethyl ammonium bromide (DMRE), 
3β[N-(N',N'-dimethylaminoethane)-carbomoyl] cholesterol 
(DC-CHOL), and dioctadecylamino-glycyl-spermine (DOGS 
or Transfectam
®) (Mahato 2005).
Figure 6  Chemical structures of the cationic lipids: 
dioleoylphophatidylethanolamine (DOPE), N-[1- dioleyloxy)propyl]-N,N,N-
trimethylammonium (DOTMA) and 1,2-bis(oleoyloxy)-3-(trimethylammonio)p
ropane (DOTAP).
Figure 5  Schematic representation of conventional, stealth, targeted 
liposomes, and virosomes. Among different mechanism of intracellular uptake 
of liposomes, endocytosis of targeted liposomes is exemplified.
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Nevertheless, the clinical use of cationic liposomes is 
limited by their instability, rapid clearance, large particle 
size, toxicity at repeated administration, and induction of 
immunostimulation and complement activation. Water-
soluble lipopolymers, obtained by conjugating different fatty 
acid chains to branched polethylenimine (PEI) of 25 kDa or 
above, have been shown to be effective for gene delivery; 
they can be delivered into the cytoplasm after endosomal 
disruption. Similarly, phosphatidyl ethylene glycol (PhosEG) 
has been linked to the amino group of branched PEI (Mahato 
2005).
On the other hand, PEGylation of cationic liposomal 
vesicles is a promising alternative way to overcome these 
problems, prolonging circulation time in vivo and increasing 
accumulation at the disease site, even if the transfecting 
efficiency might be significantly reduced.
In liposomes composed of a cationic lipid (DOTAP, 
DOGS, dimethyldioctadecylammonium bromide-DDAB), 
a neutral lipid (DOPE) and a phospolipid derivative of PEG 
(PEG-PE), complexing 18-mer phosphothioate as a model for 
active oligodexyribonucleotide (ODN), surface modification 
with a relatively large amount of PEG (5.7 mol%) has been 
showed to improve ODN loading without losing structural 
activity or stability of the resulting complexes, retaining size 
without vesicle aggregation. Moreover, the hydrophilic shell 
of PEG enhances the in vitro stability by evading mononuclear 
phagocyte clearance, and retains a high level of the originally 
loaded ODN in the complex after plasma incubation. Only 
after modification of PEG cationic liposomes with targeting 
agents can cytoplasmatic delivery of DNA material be 
observed. The PEG-modified complex conjugated anti-HER2 
F(ab') dramatically enhanced cell uptake, increasing diffuse 
cytoplasmatic and nuclear localization of ODN in SK-BR-3 
cells (Meyer et al 1998).
In liposomes composed of DODAC/DOPE, the inclusion 
of 5 mol% of PEG lipid conjugate did not inhibit uptake by 
the cell membrane of lipid/DNA complex, but substantially 
modified the ability of the cationic liposomal carrier to 
disrupt the endosomal membrane. Endosomal escape into the 
cytoplasm depended on the acyl chain of the lipid complex 
and on the molecular weight of the PEG. Optimizing the 
desorbtion rate of PEG-lipids may be one approach to 
overcoming the inhibitory effect on intracellular delivery of 
plasmid (Song et al 2002).
To contrast the low tranfection efficiency of PEG-modified 
cationic liposomes due to the absence of a net positive charge 
on the vesicle surface, a series of cationic PEG-lipids with one 
or more positive charges have been synthesized and designed 
for post-insertion in preformed stabilized plasmid-lipid 
particles (Figure 7). Incorporation of cationic-poly(ethylene 
glycol)-lipid conjugates (CPL4) in DOPE/DODAC/PEG-
CerC20 liposomes resulted in both improved uptake into 
BHK cells and dramatically enhanced transfection potency 
in the presence of Ca
2+, which assists in destabilizing the 
endosomal membrane following uptake. However, in this 
type of liposomal preparation, aggregation of vesicles was 
observed, probably due to formation of H-bonding between 
the amino and carbonyl groups present in the distal head-
group at the end of the PEG chain (Palmer et al 2003). In 
order to optimize CLP-liposomes for systemic delivery, the 
length of PEG linker in the CPL can be modulated. When the 
PEG3400 linker extended beyond the PEG-CerC20 “cloud” 
was employed for liposomal insertion, charged liposomal 
systems were produced that rapidly cleared from circulation; 
it was suggested that a shorter PEG linker might be used, such 
as PEG1000, allowing the PEG-CerC20 to shield the positive 
charge of CPL. Moreover, PEG-CerC20 can be designed to 
slowly dissociate at the disease site, achieving exposure of 
the CPL at the target area with retention of long-circulation 
properties and interaction between liposomes and targeting 
cell (Chen et al. 2004).
Overall, the most suitable use of PEG is as a tether for a 
specific ligand on the surface of these systems, in order to obtain 
a target-specific gene delivery facilitating internalization in 
cells and endosomal escape. Cell-penetrating peptides (CPP), 
such as Trans-activating transcriptional activator (TAT), 
homeodomain of antennapedia (Antp), herpex simplex virus 
type I protein VP22 and transportan, have been reported to 
guarantee direct cytosolic delivery when coupled with several 
carriers, including liposomes. Multiple TATp molecules can 
be attached on the surface of liposomes via the spacer group 
of p-nitrophenylcarbonyl-PEG-phosphatidylethanolamine. 
Figure 7  Structure of dansylated cationic-poly(ethylene glycol)-lipid (CPL4) 
and schematic representation of the post-insertion method for the production 
of CPL4 liposomes (redrawn from Palmer et al 2003).International Journal of Nanomedicine 2006:1(3) 310
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TATp-liposomes-DNA complexes were found to be capable 
of transfection of both normal and cancer cells in vitro and 
in vivo with lower cytotoxicity that the commonly used lipid-
based gene delivery systems (Gupta et al 2005).
Liposomes for diagnostic imaging
Actively or passively targeted liposomes can be used as 
carriers for contrast agents to increase the signal difference 
between areas of interest and background, and to specifically 
localize the contrast moieties in the target tissues or organs. 
The versatility of liposomal vesicles to carry different types 
of compound in the bilayer or in the aqueous compartment 
makes them suitable for all contrast procedures, including 
gamma-scintigraphy, magnetic resonance imaging (MRI), 
computed tomography imaging (CTI), and sonography. Using 
liposomes in diagnostic imaging leads to several advantages, 
owing to their capability to incorporate multiple contrast 
moieties, to specifically deliver the agent to the target area, 
and to enhance the contrasting signal.
In order to incorporate diagnostic agents (
111In, 
99Tc, Mn, 
Gd, etc) in liposomes, metals can be complexed with a soluble 
chelating agent (such as DTPA) that will be encapsulated in 
the aqueous core of the vesicles. Alternatively, the chelating 
compound complexing with the metal can be derivatized 
with a hydrophobic group for insertion in the lipid bilayer. 
Gd-DTPA complexes were the first to be incorporated in 
the aqueous core. Among the various lipophilic DTPA–
conjugates that have been synthesized, DTPA-sterylamine 
(DTPA-SE) and DTPA-phosphatidyl ethanolamine (DTPA-
PE) show reduced leakage and toxicity of potentially toxic 
metals. (DTPA-polylysil)glutaryl phosphatidyl ethanolamine 
(DTPA-PLL-NGPE) is a poly-chelating amphiphilic polymer 
suitable for liposome incorporation that drastically increases 
the number of metal ions attached to a single lipid conjugate. 
In these cases, metals are situated on the liposomal surface, 
directly exposed to the aqueous environment, thus enhancing 
the contrast proprieties.
To increase the stability and half-life of vesicles in the 
body after administration, liposomes for use as contrast agent 
can be modified with PEG. DTPA-PLL-NGPE liposomes 
with PEG5000 containing Gd improved visualization in the 
lymph nodes: PEG moieties increase the amount of water 
directly in contact with the Gd on the liposomal surface, and 
contrast phagocytic cell uptake at the injection site.
Long-circulating Gd liposomes have been successfully 
used for blood pool imaging, prolonging the presence of the 
contrast agent in the body. After systemic administration 
of Gd-DTPA-PLL-NGPE/PEG-liposomes, the signal was 
immediately clear and lasted for up to 4 hours (Torchilin 
2000).
Incorporation of large amount of Gd-containing lipids 
in sterically stabilized PEGylated DSPC- or DOPC-based 
liposomes showed increased relaxivity compared with 
traditional Gd-DTPA; because of the higher accessibility of 
water, liposomes containing unsaturated phospholipids also 
showed increased relaxivity in comparison with liposomes 
composed of saturated phospholipids. These liposomes are 
therefore highly potent contrast agents for application in MR 
imaging (Strijkers et al 2005).
Liquid-filled liposomes have been demonstrated to 
be echogenic. The liquid-like composition of the vesicles 
makes them more resistant to pressure and mechanical 
stress than encapsulated gas microbubbles. Moreover, their 
long circulation characteristics and their small size are 
favorable in echography. Definity
® (Bristol-Myers Squibb 
Medical Imaging, Inc. New York, NY, USA) is a contrast 
agent containing perfluoropropane with a phospholipid shell 
approved in the US for use in cardiology.
After lyophilization, liposomes can encapsulated small 
amounts of air, being echogenic upon rehydration. Is it 
possible to modulate the liposomal composition by changing 
the ratio between PC, PE, PG, and CHOL to produce agents 
that are echogenic in vitro and in vivo (Dayton and Ferrara 
2002). Echogenic liposomes have also been utilized for 
intravascular ultrasound imaging, targeting the vesicles to 
the vascular signature associated with arteroma development 
(Morawski et al 2005).
A pH liposomal MRI contrast agent has recently been 
introduced as a potential marker of low pH in tumor 
interstitium. DPPE/DSPG/GdDTPA-BMA liposomes 
displayed increased relaxivity in the blood when the pH 
was below the physiological level, due to aggregation and 
leakage of GdDTPA-BMA. To optimize these liposomal 
formulations it is necessary that they retain pH sensitivity 
in the blood and accumulate in the tumor. Blood circulation 
time was prolonged by incorporating 1.5mol% in DPPE/
DSPG liposomal GdDTPA-BMA, but the pH-response was 
reduced. A compromise would be necessary between long 
blood retention and pH-sensitivity (Lokling et al 2004).
Liposomes for vaccines
Genetic vaccination-encoding antigens from bacteria, virus, 
and cancer has shown promise in protecting humoral and 
cellular immunity. The success of liposomes-based vaccines 
has been demonstrated in clinical trials and further human 
trials are also in progress.  Liposomes are of interest as International Journal of Nanomedicine 2006:1(3) 311
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carriers of antigens, especially because they act as effective 
adjuvants for the immune system response, without 
causing granulomas at the injection site and producing no 
hypersensitivity reactions (Chen and Huang 2005). Liposome 
formulations would also protect their DNA content from 
deoxyribonuclease attack. Moreover, their transfection 
efficiency could be improved by modulating surface charge, 
size, and lipid composition of the vesicle and entrapping 
additional adjuvant or immunostimulator compounds in the 
antigen formulation. Several strategies have been followed 
to target liposomes to cell receptors, such as antibodies (or 
Fc-γ) or branched chain mannose moieties. Cationic or pH-
sensitive liposomes that are able to release their contents 
into the cytoplasm following endocytosis have also been 
developed.
Two commercial vaccines based on virosome technology 
are currently on the market. Epaxal
® (Berna Biotech Ltd, 
Bern, Switzerland), a hepatitis A vaccine, has inactivated 
hepatitis A virus particles adsorbed on the surface of the 
immunopotentiating reconstituted influenza virosomes 
(IRIV). In Inflexal
® V (Berna Biotech Ltd) the virosome 
components themselves are the vaccine protective antigens 
(Copland et al 2005). Virosomes are liposomal formulations 
that have viral envelope proteins anchored to their 
lipid membrane. The lipid bilayer is composed of PC 
intercalated with the virus-derived proteins hemagglutinin 
and neuraminidase. These virus-like particles have proven 
to be effective immunogens with unique adjuvant properties 
(Felnerova et al 2004).
Liposome-encapsulated malaria vaccine contains 
monophosphoryl lipid A as adjuvant in the bilayer and the 
formulation is adsorbed on aluminum hydroxide. In a Phase 
I dose-escalating study, the formulation showed induction 
of higher level of anti-malaria antibody in human volunteers 
(Chen and Huang 2005).  Some liposomal formulations are 
under investigation in preclinical studies against Yersina 
pestis, ricin toxin and Ebola Zaire virus. Liposomes against 
ricin or pestis, composed of PC/CHOL/DDA containing 
KWC vaccine, were administered intranasally to C57BL/6 
mice; liposome formulations gave higher protection from 
infection than KWC in buffer. Liposomes composed of PC 
and CHOL containing ricin toxoid and ricin A-chain (rA) 
increased antibody responses to the rA chain. Liposomes 
composed of DMPC/DMPG/CHOL with or without lipid A 
containing Ebola Zaire virus have been tested in mice and 
cynomolgus monkeys (Bramwell et al 2005).
Liposome vaccination also has the potential to be a 
powerful weapon in cancer treatment. Chen et al (Chen and 
Huang 2005) developed a novel liposome-based system 
for the delivery of plasmid DNA. Lipid-polycation-DNA 
particles are formed by combining cationic liposomes 
and polycation-condensed DNA organized in a virus-like 
structure able to release its content in the cytoplasm. Cationic 
liposomes promote a much higher humoral and cytotoxic T 
lymphocyte immune response against the antigen encoded 
by the entrapped DNA vaccine. Liposome-stabilized prostate 
cancer vaccine is under investigation in a series of Phase 
I trials in patient with advanced prostate cancer. The new 
liposome-lipid A-prostate-specific antigen formulation 
showed greater safety and higher immunological potency 
than other formulations and has been transitioned to Phase 
II trials (Chen and Huang 2005).
Other pharmaceutical uses of stealth 
liposomes
Active research is in progress in the area of liposomes for 
use as vesicular containers, in particular for hemoglobin 
as blood substitute. Liposome-encapsulated hemoglobin 
(LEH) is being developed as an oxygen therapeutic. The 
spatial isolation of hemoglobin by a lipid bilayer potentially 
minimizes the cardiovascular/hemodynamic effects associated 
with other modified forms of hemoglobin; moreover, it is 
possible to co-encapsulate reductants, antioxidative enzyme 
systems, and oxygen-affinity modifiers with hemoglobin 
so as to artificially recreate the red blood cell environment. 
The circulation half-life is 65 hours for this PEG-LEH 
formulation; the results demonstrate that LEH circulates for 
a prolonged time after administration and that the animals 
tolerate at least 25% of blood exchange without any distress 
(Phillips et al 1999; Arifin and Palmer 2005).
Conclusions
The development of liposomes as carriers for therapeutic 
molecules is an ever-growing research area. The possibility 
of modulating the technological characteristics of the vesicles 
makes them highly versatile both as carriers of several types 
of drug (from conventional chemotherapeutics to proteins 
and peptides) and in therapeutic applications (from cancer 
therapy to vaccination). In recent years, several important 
formulations for the treatment of different diseases have 
been developed. Among these, PEG-coated liposomes are 
becoming increasingly important, giving technological and 
biological stability to liposomal systems. At present, few 
PEGylated liposomal formulations have been approved or 
are in advanced trials (DOXIL, SPI077, Lipoplatin, S-CKD-International Journal of Nanomedicine 2006:1(3) 312
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602), but stealth technology for different applications is 
destined to continue developing. PEG-derivatized liposomes 
with increased stability can easily be modified using a 
wide array of targeting moieties (MAb, ligands) to deliver 
the drug specifically to the target tissues with increasing 
accuracy. Moreover, PEG grafted onto the liposome surface 
can guide the liposome to a specific intracellular target, 
using for example cell-penetrating proteins and peptides as 
targeting agents. The development of liposome delivery to 
particular subcellular compartments is a field of great interest 
in different fields, such as gene therapy and vaccination. The 
interaction of stealth liposomes with cell membranes, and 
release of the drug in the neighborhood of target tissues are 
still under investigation, but some recent studies indicate that 
the use of detachable PEG may facilitate cell penetration 
and/or intracellular delivery of vesicles. 
Taking into account these considerations and the great 
advantages of PEGylated liposomes in decreasing aspecific 
drug toxicity and in passively targeting the incorporated 
molecules to the site of action, new and “improved” stealth 
liposomal formulations designed for different therapeutic 
and diagnostic areas may soon be expected to arrive on the 
market.
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